Personalis, Inc.

Listed Company

PSNLCIK 0001527753NasdaqNon-AcceleratedSmaller ReportingServices-Medical LaboratoriesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$69.65M

Net Income

$-81.27M

Total Assets

$334.16M

Equity

$261.19M

Shares Out

104.72M

Op. Cash Flow

$-74.95M

Business

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and sequencing services used for translational research, biomarker discovery, personalized cancer therapies, clinical trials, and patient monitoring. Its main products and services include tumor-informed liquid biopsy MRD tests (NeXT Personal, NeXT Personal Dx), comprehensive tumor profiling (NeXT Dx, ImmunoID NeXT), and whole exome/genome sequencing (WES/WGS) for diagnostic partners and population initiatives. The company manages one operating segment focused on providing advanced cancer genomic tests and services for precision oncology and personalized testing. It sells primarily in the United States, Europe and Asia-Pacific through a small direct sales force and strategic co-commercialization partnerships (including Tempus) to pharmaceutical, diagnostics, academic, government and patient customers.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	70	85	73	65	85
Cost of revenue	54	58	55	52	54
Research and development	50	49	65	65	49
Selling, general and administrative	54	46	50	64	48
Total costs and expenses	158	153	183	181	151
Loss from operations	−88	−68	−110	−116	−65
Interest income	7	6	6	2	367,000
Interest expense	−205,000	−24,000	−110,000	−201,000	−184,000
Other income (expense), net	−142,000	−18	−4	61,000	−42,000
Loss before income taxes	−81	−81	−108	−113	−65
Provision for income taxes	21,000	18,000	83,000	40,000	14,000
Net loss	−81	−81	−108	−113	−65
Net loss per share, basic	−0.91	−1.37	−2.25	−2.48	−1.49
Net loss per share, diluted	−0.91	−1.37	−2.25	−2.48	−1.49
Weighted-average shares outstanding, basic	89	59	48	46	44
Weighted-average shares outstanding, diluted	89	59	48	46	44

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	124	91	57	89	106
Short-term investments	116	94	57	79	181
Accounts receivable, net	16	8	18	17	18
Inventory and other deferred costs	6	6	10	9	6
Prepaid expenses and other current assets	6	4	4	7	7
Total current assets	268	203	147	200	318
Property and equipment, net	45	48	57	62	20
Operating lease right-of-use assets	15	16	18	26	54
Other long-term assets	6	3	3	5	5
Total assets	334	270	225	293	397
Accounts payable	13	6	15	13	9
Accrued and other current liabilities	25	22	24	19	18
Contract liabilities	2	3	3	1	4
Total current liabilities	40	31	47	33	31
Long-term operating lease liabilities	32	35	38	41	53
Other long-term liabilities	1	1	5	389,000	2
Total liabilities	73	67	96	75	86
Commitments and contingencies (Note 11)	—	—	—	—	—
Preferred stock, $0.0001 par value 10,000,000 shares authorized; none issued	—	—	—	—	—
Common stock, $0.0001 par value - 200,000,000 shares authorized; 102,475,891and 85,171,146 shares issued and outstanding, respectively	10,000	9,000	5,000	5,000	4,000
Additional paid-in capital	892	753	598	579	558
Accumulated other comprehensive income (loss)	104,000	−23,000	−222,000	−912,000	−166,000
Accumulated deficit	−631	−550	−469	−360	−247
Total stockholders equity	261	203	129	218	310
Total liabilities and stockholders equity	334	270	225	293	397

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−81	−81	−108	−113	−65
Stock-based compensation expense	9	11	14	19	14
Depreciation and amortization	10	11	11	8	6
Noncash operating lease cost	1	1	2	4	3
Noncash gain related to liability	—	18	—	—	—
Amortization of discount on short-term investments	−4	−3	−2	57,000	2
Other	−302,000	93,000	153,000	103,000	169,000
Accounts receivable	−8	10	−1	2	−12
Inventories and other deferred costs	−204,000	4	−2	−3	29,000
Prepaid expenses and other assets	−2	1	4	484,000	−3
Accounts payable	5	−9	5	3	−1
Accrued and other current liabilities	2	−2	742,000	−1	3
Contract liabilities	−2	−4	6	−3	−17
Operating lease liabilities	−4	−4	894,000	13	−962,000
Other long-term liabilities	−1	1	−10,000	−419,000	−291,000
Net cash used in operating activities	−75	−45	−56	−70	−71
Purchases of available-for-sale debt securities	−210	−122	−104	−121	−267
Proceeds from maturities of available-for-sale debt securities	192	88	128	224	213
Purchases of property and equipment	−5	−2	−11	−50	−11
Proceeds from sales of property and equipment	—	242,000	—	—	—
Net cash used in investing activities	−23	−35	13	53	−60
Proceeds from sales of common stock under ATM facility, net of commissions	127	30	4	—	162
Proceeds from exercise of Tempus Warrants	—	18	—	—	—
Proceeds from sale of common stock under Tempus Investment Agreement	—	18	—	—	—
Proceeds from sale of common stock under Merck Investment Agreement	—	50	—	—	—
Payment of costs related to Tempus and Merck Investment Agreements	−189,000	−1	—	—	—
Proceeds from loans	3	—	3	1	5
Repayments of loans	−2	−1	−3	−2	−2
Proceeds from issuance of common stock under equity incentive plans	3	770,000	1	—	—
Net cash provided by financing activities	130	115	11	1	170
Effect of exchange rates on cash, cash equivalents and restricted cash	6,000	−22,000	−16,000	−127,000	47,000
Net change in cash, cash equivalents and restricted cash	33	34	−32	−16	39
Cash paid for income taxes, net of refunds	23,000	38,000	64,000	47,000	39,000
Acquisition of property and equipment included in accounts payable and accrued liabilities	3	473,000	104,000	4	3
Finance lease assets obtained in exchange for finance lease liabilities	3	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Personalis, Inc.'s CIK number?

Personalis, Inc.'s SEC CIK number is 0001527753 (1527753). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Personalis, Inc.'s SEC filings?

All of Personalis, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Personalis, Inc. last report earnings?

Personalis, Inc. (PSNL) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-211850). This is Personalis, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Personalis, Inc.'s most recent earnings 8-K?

Personalis, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-211850. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Personalis, Inc.'s latest earnings 8-K →
Look up any company's CIK number →